62 citations,
April 2004 in “Expert Opinion on Pharmacotherapy” Finasteride effectively treats male pattern baldness, improving hair growth and density.
57 citations,
February 2007 in “International Journal of Cancer” A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
35 citations,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
35 citations,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
30 citations,
July 2019 in “Endocrinology” Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.
29 citations,
September 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” Finasteride and dutasteride effectively treat hair loss in men and women, but may cause side effects like low libido and depression.
28 citations,
June 2010 in “European Journal of Cancer” Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.
26 citations,
June 2005 in “Journal of Molecular Endocrinology” Dutasteride is more efficient than finasteride, but individual results vary.
25 citations,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
22 citations,
October 2018 in “Aesthetic Plastic Surgery” Understanding hair follicle biology and stem cell control could lead to new hair loss treatments.
17 citations,
January 2016 in “American Journal of Epidemiology” Men with male pattern baldness have a higher risk of dying from prostate cancer.
17 citations,
February 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early balding at 40 increases prostate cancer risk.
14 citations,
January 2004 in “BJUI” Finasteride can treat prostatic haematuria, but its use is controversial.
12 citations,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
10 citations,
June 2010 in “Expert Opinion on Drug Metabolism & Toxicology” Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.
10 citations,
October 2010 in “International Journal of Andrology” Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
9 citations,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
7 citations,
May 2012 in “International Journal of Andrology” The new oral testosterone pill normalized testosterone levels and lowered SHBG in men with low testosterone.
4 citations,
July 2021 in “Journal of Dermatological Treatment” Finasteride helps hair growth but may cause sexual side effects and depression.
4 citations,
June 2015 in “Journal of Genetics/Journal of genetics” Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
3 citations,
March 2018 in “BMC Cancer” Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
3 citations,
May 2010 in “Archives of dermatology” Herpes zoster infection can cause permanent hair color change in the affected area.
3 citations,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
1 citations,
August 2013 in “Journal of the National Cancer Institute” Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.
May 2024 in “Brazilian Journal of Hair Health” Finasteride and dutasteride may help prevent hair loss but could cause side effects like sexual dysfunction and psychological issues.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.